hs-CRP, fully explained: the inflammation marker your standard cholesterol panel doesn't capture.

What hs-CRP actually is

hs-CRP — high-sensitivity C-reactive protein — is a protein produced by the liver in response to inflammation anywhere in the body. The "high-sensitivity" version of the test detects very low concentrations, low enough to identify chronic, low-grade inflammation rather than just acute infection[1]. Standard CRP tests are calibrated to detect the much higher levels associated with bacterial infection, recent surgery, or autoimmune flare. hs-CRP measures the same protein but at a sensitivity that lets clinicians use it as a cardiovascular risk marker.

The reason this matters: chronic, low-grade inflammation is now understood as a central driver of atherosclerosis — the process by which arteries narrow and harden over time[2]. Even at concentrations far below those that signal infection, persistently elevated hs-CRP is associated with increased risk of heart attack, stroke, and cardiovascular death[3].

What's a "normal" hs-CRP level?

The American Heart Association and Centers for Disease Control jointly published reference ranges for hs-CRP as a cardiovascular risk marker in 2003, and these have remained the clinical standard[4]:

These categories are statistical, not biological — they reflect the cardiovascular risk distribution of the populations the studies were drawn from. They tell you where you sit relative to other people, not where you sit relative to your own optimum[5].

That's why "borderline" results — values in the 2.0–3.0 mg/L range — deserve attention even though they're technically inside the lab's "normal" reference. Multiple large meta-analyses have shown that the relationship between hs-CRP and cardiovascular events is continuous: every increment higher carries incremental risk, and the per-standard-deviation hazard ratios remain meaningfully elevated even within the "average" range[3].

What 160,309 people taught us about hs-CRP

The single most important study on hs-CRP and cardiovascular risk is the 2010 individual-participant meta-analysis from the Emerging Risk Factors Collaboration, published in The Lancet[3]. Researchers pooled data from 54 long-term prospective studies covering 160,309 people without prior cardiovascular disease, with a median follow-up of 11.7 years.

The headline finding: a per-standard-deviation increase in hs-CRP was associated with a hazard ratio of 1.37 (95% CI 1.27–1.48) for coronary heart disease, independent of all traditional cardiovascular risk factors. That means even after adjusting for age, sex, smoking, blood pressure, cholesterol, and diabetes, hs-CRP added significant predictive information.

The paper concluded that hs-CRP measurement modestly but meaningfully improves cardiovascular risk prediction beyond traditional risk factors, and is particularly valuable in people whose Framingham risk score puts them in the intermediate risk category — the population for whom additional risk markers can change clinical decisions.

The Reynolds Risk Score: hs-CRP plus a family history

In 2007, Paul Ridker — the cardiologist who has driven much of the research on hs-CRP — published the Reynolds Risk Score, which augmented the Framingham Risk Score by adding hs-CRP and parental history of premature heart disease[6]. In a study of nearly 25,000 women followed for over 10 years, the Reynolds Risk Score reclassified about 30 percent of women considered "intermediate risk" by Framingham into either lower or higher risk categories, with the new classification more accurately matching their actual cardiovascular event rates.

This is one of the cleanest demonstrations of why hs-CRP matters in routine practice: not as a standalone screen, but as an additional input that sharpens decisions for the people whose risk is otherwise ambiguous.

JUPITER: hs-CRP as a target for treatment

The 2008 JUPITER trial took the question further: if hs-CRP predicts cardiovascular events independent of cholesterol, can lowering hs-CRP change outcomes?[7] The trial randomized 17,802 apparently healthy people with LDL cholesterol below 130 mg/dL but elevated hs-CRP (≥ 2.0 mg/L) to either rosuvastatin 20 mg daily or placebo.

The trial was stopped early after a median follow-up of just 1.9 years because the benefit was so clear. The statin group experienced a 44% reduction in major cardiovascular events compared to placebo, including a 54% reduction in heart attacks and a 48% reduction in strokes. Their LDL dropped 50%, and their hs-CRP dropped 37%.

The implication: in people with elevated hs-CRP and otherwise "normal" cholesterol, intervention can produce substantial cardiovascular benefit. JUPITER reshaped how cardiology thinks about primary prevention and added hs-CRP to the risk-stratification toolkit of every major cardiology society.

What lowers hs-CRP — what the intervention research shows

This is the part most people actually care about: if your hs-CRP is elevated, what does the peer-reviewed research say you can do about it?

Omega-3 fatty acids (EPA + DHA)

Omega-3 supplementation is one of the most-studied interventions for hs-CRP. A 2026 systematic review and meta-analysis pooled 14 randomized controlled trials covering 2,214 participants and found that EPA+DHA supplementation at typical clinical doses (1–4 g/day) was associated with a mean reduction in hs-CRP of approximately 0.8 mg/L over 12 weeks, with the largest effects in participants whose baseline hs-CRP fell between 2.0 and 5.0 mg/L[8]. Earlier meta-analyses have reported similar findings[9]. The effect appears independent of weight change and concurrent statin use.

Mediterranean diet

The PREDIMED trial — a major Spanish randomized trial of the Mediterranean diet for cardiovascular prevention — measured hs-CRP as a secondary outcome and found significant reductions in the diet-intervention groups compared to a low-fat control diet, particularly in the group supplemented with extra-virgin olive oil[10]. Multiple subsequent studies have confirmed that adherence to a Mediterranean dietary pattern is associated with lower baseline hs-CRP levels in observational and interventional designs[11].

Exercise

Regular aerobic exercise lowers hs-CRP. A 2017 meta-analysis of 83 randomized trials covering more than 3,500 participants found that aerobic training programs reduced hs-CRP by an average of approximately 1.0 mg/L, with the largest effects in people who were overweight at baseline and in studies with longer training durations[12]. Resistance training alone has shown smaller and less consistent effects.

Weight loss

In overweight individuals, even modest weight loss (5–10% of body weight) is consistently associated with significant reductions in hs-CRP across multiple intervention trials and observational cohorts[13]. The effect appears to scale with the magnitude of weight loss and is mediated in part by reductions in visceral adipose tissue, which is metabolically active and produces inflammatory cytokines.

Sleep

Short sleep duration (less than 6 hours per night) is associated with elevated hs-CRP in cross-sectional studies, and improving sleep duration in deprived individuals is associated with measurable reductions in inflammatory markers[14]. The relationship is bidirectional and dose-dependent.

Smoking cessation

Active smokers have higher hs-CRP than non-smokers on average, and quitting is associated with measurable reductions in hs-CRP within months[15]. The effect is one of the largest single-intervention reductions documented in the inflammation literature.

Statins (when clinically indicated)

Statins lower hs-CRP independent of their effect on LDL cholesterol. JUPITER[7] and subsequent analyses have confirmed that the cardiovascular benefit of statin therapy in primary prevention is partly mediated by hs-CRP reduction. Whether to start a statin is a clinical decision that depends on individual risk; this article does not recommend medication.

What hs-CRP doesn't tell you

hs-CRP is a sensitive but non-specific marker. Elevated values don't tell you why inflammation is present. Possible causes include cardiovascular disease, but also obesity, autoimmune conditions, recent infection, periodontal disease, ongoing low-grade infections, environmental exposures, and high stress.

One single elevated hs-CRP measurement also doesn't establish chronic elevation. Because hs-CRP can spike acutely with any infection or injury, a single high reading taken during an acute illness may not reflect baseline cardiovascular risk. The clinical recommendation is to confirm elevated values with a repeat test 2 weeks later, when the patient is feeling well[16].

Finally, hs-CRP is one input into cardiovascular risk, not a complete picture. ApoB (or LDL-cholesterol), Lp(a), blood pressure, glucose tolerance, family history, smoking status, and other factors all contribute to total cardiovascular risk. A useful interpretation requires the full picture, not a single marker in isolation.

Where hs-CRP fits with ApoB, Lp(a), and the rest of the cardiovascular workup

In 2026, the most informative cardiovascular blood workup includes: total cholesterol, HDL, LDL, non-HDL, triglycerides, apolipoprotein B (ApoB), lipoprotein(a) (Lp(a)), and hs-CRP — plus blood pressure, glucose, and HbA1c. Each measures something different:

• LDL and ApoB measure the cholesterol-carrying particles that drive atherosclerosis. ApoB is increasingly recognized as the more accurate measure of atherogenic particle concentration.
• Lp(a) is a largely-genetic lipoprotein particle that carries an independent and additional cardiovascular risk for people whose levels are elevated.
• hs-CRP measures systemic inflammation — a complementary, not redundant, predictor of cardiovascular events.

The major cardiology societies — including the European Society of Cardiology in its 2021 guidelines — recommend hs-CRP as an adjunct marker, particularly in people whose conventional risk score places them in the intermediate range and where the additional information may change clinical management[17].

How Lipa reads hs-CRP

When you upload a blood test to Lipa, hs-CRP is one of the first markers we read. We compare your value against the established reference ranges, your demographic profile (age, sex), and your other markers — particularly your ApoB, Lp(a), fasting insulin, and HOMA-IR. We then surface the relevant peer-reviewed research on your specific value range and produce a plain-English explanation, with every claim cited to a real study you can read on PubMed.

Lipa's Living Research engine means that when a new high-grade study on hs-CRP is published — like the 2026 omega-3 meta-analysis cited above — we pick it up within 24 hours, evaluate its evidence grade and funding source, and surface it as a personalized insight to members whose markers are relevant. You don't have to go looking for the research. It finds you.

Every Lipa hs-CRP analysis includes:

• Your value in context against optimal vs reference ranges
• The published research on intervention at your specific level
• Cross-marker context (how your ApoB, fasting insulin, and other markers interact)
• A personalized action plan with cited research on each recommendation
• Alerts when new studies on hs-CRP land in our corpus